The multi-centre, open-label trial involved 89 patients across six sites in the US and Australia. Credit: Volha_R / Shutterstock.

Vergent Bioscience has completed subject enrolment for its VISUALIZE trial, which is designed to assess the efficacy and safety of abenacianine for injection (VGT-309) in lung cancer patients.

Previous clinical studies have indicated that abenacianine for injection offers surgeons a ‘molecular sight’, allowing them to visualise tumour tissue more effectively during minimally invasive surgeries (MIS), along with the robotic-assisted methods.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase II multi-centre, open-label trial involved 89 patients across six sites in the US and Australia, each receiving a 0.32mg/kg dose of the agent 12 to 36 hours before their surgery.

During the trial, each patient was administered the injection as a short infusion before surgery. Surgeons then attempted to identify tumours using standard techniques, followed by the use of a near-infrared (NIR) endoscope to confirm the presence of tumour tissue, with pathology providing further confirmation.

The trial’s primary efficacy endpoints included intraoperative visualisation of tumours, surgical margin assessment, and the identification of additional cancers/positive lymph nodes that might not have been detected preoperatively.

Vergent Bioscience CEO and president John Santini said: “The VISUALIZE trial will provide additional, valuable insights illuminating the potential of our novel imaging agent to address existing deficits in tumour visualisation during lung surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Completing enrolment in the trial is an exciting milestone that reflects our team’s dedication, as well as the commitment of the VISUALIZE clinical investigators and study participants. We look forward to sharing the results of this study.”

Subsequent to the analysis of the trial data, Vergent plans to progress abenacianine for injection into a Phase III study.

Assuming positive outcomes from this phase, the company anticipates filing a new drug application for lung cancer surgery.

Abenacianine for injection, a tumour-targeted fluorescent imaging agent binds covalently to cathepsins, proteases that are overexpressed in various solid tumours.